KRAS and neoplasm: Importantly, our data emphasized KRAS potential role in samples with ARID1A or PIK3CA mutation in OCCC, identified LRP1B mutation group only occurred in samples with non-ARID1A truncation mutation, distinguished the potential carcinogens-exposed of those tumors by mutational signatures and unearthed several novel drivers in CNV level that might essentially contribute to OCCC tumor progression.